Atara Biotherapeutics Faces Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy ATRA?
Source: Newsfilter
- Class Action Initiated: DJS Law Group alerts investors about a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, affecting shareholders who purchased shares from May 20, 2024, to January 9, 2026, which could negatively impact the company's reputation and stock price.
- False Statements Allegations: The complaint alleges that Atara's deficient ALLELE study and manufacturing issues diminished the likelihood of FDA approval for its BLA for tabelecleucel, undermining investor confidence and market performance.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in recovery efforts, indicating potential substantial liabilities for the company that could exacerbate market concerns about its future prospects.
- Legal Team Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, leveraging extensive experience and resources to advocate for maximum returns for clients, showcasing its competitive edge in a complex legal landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRA
Wall Street analysts forecast ATRA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.960
Low
18.00
Averages
21.50
High
25.00
Current: 4.960
Low
18.00
Averages
21.50
High
25.00
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- FDA Regulatory Risks: Atara's Biologics License Application (BLA) for tabelecleucel received a Complete Response Letter (CRL) from the FDA, citing good manufacturing practice (GMP) compliance issues at a third-party facility, which heightens regulatory scrutiny and jeopardizes ongoing clinical trials.
- Stock Price Volatility: Following the CRL on January 16, 2025, Atara's stock plummeted by 40.5% to $7.83 per share, and further declined by 7.91% to $6.05 per share on January 21, 2025, due to a clinical hold, indicating severe market pessimism regarding the company's future.
- Uncertain Regulatory Outlook: On January 12, 2026, Atara received another CRL indicating that the ALLELE trial's design and analysis were inadequate for FDA approval, leading to a 56.99% drop in stock price to $5.88 per share, highlighting significant financial and operational challenges ahead for the company.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: DJS Law Group alerts investors about a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, affecting shareholders who purchased shares from May 20, 2024, to January 9, 2026, which could negatively impact the company's reputation and stock price.
- False Statements Allegations: The complaint alleges that Atara's deficient ALLELE study and manufacturing issues diminished the likelihood of FDA approval for its BLA for tabelecleucel, undermining investor confidence and market performance.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in recovery efforts, indicating potential substantial liabilities for the company that could exacerbate market concerns about its future prospects.
- Legal Team Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, leveraging extensive experience and resources to advocate for maximum returns for clients, showcasing its competitive edge in a complex legal landscape.
See More
Class Action Lawsuit Announced Against Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, indicating significant legal risks that could impact the company's stock performance.
- Basis for Lawsuit: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, potentially having a significant negative impact on the company's financial condition.
- Investor Rights Protection: Investors joining the class action will incur no out-of-pocket fees, as the law firm operates on a contingency fee basis, ensuring that investors are protected in the legal process and have the opportunity to seek compensation.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Fraud
- Lawsuit Background: Gainey McKenna & Egleston has filed a securities class action lawsuit in the Central District of California on behalf of all individuals who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, highlighting investor concerns over potential risks associated with the company.
- Regulatory Risks: The lawsuit alleges that Atara failed to disclose manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for the tabelecleucel BLA, potentially exposing the company to increased regulatory scrutiny.
- Financial Impact: These issues could significantly negatively impact Atara's business and financial condition, undermining investor confidence and potentially leading to a decline in stock price, which may affect the company's future financing capabilities.
- Investor Action: Affected investors are urged to contact the law firm before the May 22, 2026, lead plaintiff motion deadline, indicating a proactive approach to safeguarding their rights and potentially influencing the company's reputation and future investment appeal.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: The Portnoy Law Firm has filed a class action against Atara Biotherapeutics on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motions set for May 22, 2026, indicating significant legal risks that could impact the company's stock price and market confidence.
- Regulatory Scrutiny Risk: Due to manufacturing issues and deficiencies in the ALLELE study, the FDA has expressed skepticism regarding the approval prospects of Atara's tabelecleucel BLA, leading to diminished investor confidence and potentially significant negative impacts on the company's financial condition.
- Stock Price Volatility: Following the receipt of a Complete Response Letter (CRL) on January 16, 2025, Atara's stock plummeted from $13.16 to $7.83, a 40.5% decline, reflecting market pessimism regarding the approval prospects of its product.
- Clinical Trials Halted: On January 21, 2025, the FDA placed a clinical hold on Atara's trials due to unresolved GMP compliance issues, causing an 8% drop in stock price, highlighting the company's challenges in regulatory compliance that may hinder future R&D progress.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, alleging that the company made false and misleading statements that led to investor losses.
- Compensation Structure: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, with a lead plaintiff required to file by May 22, 2026, highlighting the urgency of the legal process and potential benefits for investors.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
- Potential Impact: The lawsuit claims that Atara's manufacturing and clinical trial issues could jeopardize its FDA Biologics License Application approval, likely resulting in significant negative impacts on the company's financial condition and market confidence.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Atara Biotherapeutics in the Central District of California on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026, seeking damages for violations of federal securities laws.
- FDA Regulatory Risks: Atara's Biologics License Application (BLA) for tabelecleucel received a Complete Response Letter (CRL) from the FDA, citing good manufacturing practice (GMP) compliance issues at a third-party facility, which heightens regulatory scrutiny and jeopardizes ongoing clinical trials.
- Stock Price Volatility: Following the CRL on January 16, 2025, Atara's stock plummeted by 40.5% to $7.83 per share, and further declined by 7.91% to $6.05 per share on January 21, 2025, due to a clinical hold, indicating severe market pessimism regarding the company's future.
- Uncertain Regulatory Outlook: On January 12, 2026, Atara received another CRL indicating that the ALLELE trial's design and analysis were inadequate for FDA approval, leading to a 56.99% drop in stock price to $5.88 per share, highlighting significant financial and operational challenges ahead for the company.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: DJS Law Group alerts investors about a class action lawsuit against Atara Biotherapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, affecting shareholders who purchased shares from May 20, 2024, to January 9, 2026, which could negatively impact the company's reputation and stock price.
- False Statements Allegations: The complaint alleges that Atara's deficient ALLELE study and manufacturing issues diminished the likelihood of FDA approval for its BLA for tabelecleucel, undermining investor confidence and market performance.
- Investor Losses: Affected shareholders are encouraged to contact DJS Law Group to participate in recovery efforts, indicating potential substantial liabilities for the company that could exacerbate market concerns about its future prospects.
- Legal Team Expertise: DJS Law Group specializes in securities class actions and corporate governance litigation, leveraging extensive experience and resources to advocate for maximum returns for clients, showcasing its competitive edge in a complex legal landscape.
See More
Class Action Lawsuit Announced Against Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics (NASDAQ: ATRA) securities between May 20, 2024, and January 9, 2026, indicating significant legal risks that could impact the company's stock performance.
- Basis for Lawsuit: The lawsuit alleges that Atara made false and misleading statements during the class period, failing to disclose manufacturing issues and clinical trial risks, which led to investor losses when the true information was revealed, potentially having a significant negative impact on the company's financial condition.
- Investor Rights Protection: Investors joining the class action will incur no out-of-pocket fees, as the law firm operates on a contingency fee basis, ensuring that investors are protected in the legal process and have the opportunity to seek compensation.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Atara Biotherapeutics Faces Class Action Lawsuit Over Securities Fraud
- Lawsuit Background: Gainey McKenna & Egleston has filed a securities class action lawsuit in the Central District of California on behalf of all individuals who purchased Atara Biotherapeutics securities between May 20, 2024, and January 9, 2026, highlighting investor concerns over potential risks associated with the company.
- Regulatory Risks: The lawsuit alleges that Atara failed to disclose manufacturing issues and deficiencies in the ALLELE study, which diminished the likelihood of FDA approval for the tabelecleucel BLA, potentially exposing the company to increased regulatory scrutiny.
- Financial Impact: These issues could significantly negatively impact Atara's business and financial condition, undermining investor confidence and potentially leading to a decline in stock price, which may affect the company's future financing capabilities.
- Investor Action: Affected investors are urged to contact the law firm before the May 22, 2026, lead plaintiff motion deadline, indicating a proactive approach to safeguarding their rights and potentially influencing the company's reputation and future investment appeal.
See More
Atara Biotherapeutics Faces Class Action Lawsuit
- Class Action Initiated: The Portnoy Law Firm has filed a class action against Atara Biotherapeutics on behalf of investors who purchased securities between May 20, 2024, and January 9, 2026, with a deadline for lead plaintiff motions set for May 22, 2026, indicating significant legal risks that could impact the company's stock price and market confidence.
- Regulatory Scrutiny Risk: Due to manufacturing issues and deficiencies in the ALLELE study, the FDA has expressed skepticism regarding the approval prospects of Atara's tabelecleucel BLA, leading to diminished investor confidence and potentially significant negative impacts on the company's financial condition.
- Stock Price Volatility: Following the receipt of a Complete Response Letter (CRL) on January 16, 2025, Atara's stock plummeted from $13.16 to $7.83, a 40.5% decline, reflecting market pessimism regarding the approval prospects of its product.
- Clinical Trials Halted: On January 21, 2025, the FDA placed a clinical hold on Atara's trials due to unresolved GMP compliance issues, causing an 8% drop in stock price, highlighting the company's challenges in regulatory compliance that may hinder future R&D progress.
See More
Class Action Lawsuit Filed Against Atara Biotherapeutics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Atara Biotherapeutics (NASDAQ:ATRA) securities between May 20, 2024, and January 9, 2026, alleging that the company made false and misleading statements that led to investor losses.
- Compensation Structure: Investors may be entitled to compensation without any out-of-pocket costs through a contingency fee arrangement, with a lead plaintiff required to file by May 22, 2026, highlighting the urgency of the legal process and potential benefits for investors.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its strength and experience in handling similar cases.
- Potential Impact: The lawsuit claims that Atara's manufacturing and clinical trial issues could jeopardize its FDA Biologics License Application approval, likely resulting in significant negative impacts on the company's financial condition and market confidence.
See More
